Prognosis
J&J’s Quest for Elusive HIV Vaccine Is Poised for Major Test
- Immunization aims for global protection, multiple populations
- Road to an effective vaccine has been littered with pitfalls
Photographer: Claudio Reyes/AFP via Getty Images
This article is for subscribers only.
Johnson & Johnson is preparing to test an experimental HIV vaccine in the U.S. and Europe in a move toward developing the first immunization against the deadly disease after decades of frustration.
Some 3,800 men who have sex with men will receive a regimen of shots in a study that’s planned to be launched later this year, Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said in an interview. The agency and the HIV Vaccine Trials Network of testing sites will collaborate with J&J’s Janssen unit on the effort.